[{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Center for Advanced Research and Education","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Enrolls First Patient in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Announces IND Submission to US FDA for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax\u2019s CpG 1018 Doses First Participant in Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Medigen Vaccine Biologics"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Golden Biotechnology"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoldenBiotech\u2019s New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Golden Biotechnology"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial of Antroquinonol Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Golden Biotechnology"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for UB-421 Monotherapy and in Combination with Chidamide Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"United BioPharma"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID\/NIH Recognizes the Potency of Ub-421 Against Multi-drug Resistant HIV and Receives the FDA Approval to Conduct a Phase 2 Clinical Trial With Ub-421","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"United BioPharma"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.9 million","newsHeadline":"TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"TaiGen Biotechnology"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Y.S.P. Industries M Sdn Bhd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Enters Exclusive License Agreement with YSP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"TaiGen Biotechnology"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants and other viruses.
CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways. It is expected to be clinically effective against the community-acquired pneumonia caused by viral infection.
Under the agreement, Y.S.P. will develop and commercialize TaiGen's new small molecule drug, TG-1000, a virus replication inhibitor, for infections, in Malaysia and Singapore.
CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants and other viruses.
Joincare will develop and commercialize TG-1000, a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, revealing efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses, in china.
UB-421 is an Fc-aglycosylated, non-T cell depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 (domain 1), and competitively blocks HIV entry.
Silmitasertib is a first-in-class small molecule drug that targets the CK2 pathway and acts as a CK2-inhibitor. It is safe and well-tolerated in humans. In addition to COVID-19, and is currently under development in several oncology programs in adults and children.
Antroquinonol (HOCENA®), an oral investigational small molecule has made headway with COVID-19 treatment development. Phase 2 trial can be extended recruiting hospitalized patients to severe hospitalized COVID-19 patients who need non-invasive oxygen support.
Senhwa's Silmitasertib is a CK2-inhibitor. It is thought to inhibit active viral replication in the infected cells, thereby preventing the virus from spreading to nearby cells and also reduces the body's overactive inflammatory response to Covid-19 infection.
UB-421 is a strong entry inhibitor of HIV with proven ability to substitute for ART, and it may also enhance CD8 T cell cytotoxicity function and improve immune exhaustions .